AstraZeneca’s medicine to treat a type of breast cancer gets US nod
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs
Health
Pharma
Drugs
Health
Pharma
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Drugs
Health
Medical
Eli Lilly’s Omvoh gains FDA approval for treating Crohn’s disease
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.
Drugs
Medical
Research
India’s Tata Group grants $57.8 million to build medical school in IT capital
Tata Group, a $165 billion Indian conglomerate, is set to build a medical school in the southern technology hub of Bengaluru by partnering.
Drugs
Health
Pharma
Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
Drugs
Health
Medical
Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.
Drugs
Medical
Pharma
Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.
Drugs
Pharma
Research
Pfizer’s experimental drug improves survival rates in hard-to-treat bladder cancer
Bharti Jayshankar January 11, 2024: In a breakthrough for bladder cancer treatment, Pfizer’s experimental anti-PD-1 therapy demonstrated superior efficacy compared to the current.
Drugs
Medical
Pharma
Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.
Drugs
Health
Pharma
Vertex, China’s Zai to develop, commercialise kidney disease drug
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.